Copay Assistance For Medicare Patients - The pharmacist is required to provide and review a copy of the GRANIX Patient Savings Program terms and conditions with the patient prior to opening this offer.
As a cancer patient, you and your loved ones have a wide variety of resources and support organizations ready to help you.
Copay Assistance For Medicare Patients
A national organization providing free information and support services to cancer patients, their loved ones, carers and bereaved. CancerCare provides access to educational publications and workshops, financial assistance programs, support groups and individual counseling with oncology social workers. 1-800-813-HOPE (4673)
News & Resources — United For Charitable Assistance
This is a list of resources you may find useful. Please note that this information was accurate at the time of publication but is subject to change without notice. Ask your healthcare team to recommend additional resources.
Do not take GRANIX if you have had a severe allergic reaction to filgrastim products or peg filgrastim products.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
Call your doctor for medical advice about side effects. You can report side effects to the FDA at 1-800-FDA-1088.
Starting Your Patients On Givlaari® (givosiran)
The information on this website is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States? With the ORGOVYX Copay Assistance Program, eligible commercially insured patients pay as little as $10 per month. 1-833-674-6899) See terms and conditions below.
The ORGOVYX Support Program can help patients who are not eligible for ORGOVYX
*The ORGOVYX Copay Assistance Program ("Copay Program") is for eligible patients with commercial prescription insurance for ORGOVYX. With this co-payment program, eligible patients will pay a minimum of $10 per month, up to a maximum of $10,000 per year. After the annual maximum for ORGOVYX reaches $10,000, the patient will be responsible for the remaining monthly out-of-pocket costs. This copy program may not be opened more than once in 21 days. The copayment program is not valid for patients whose prescription claims are paid in whole or in part by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs ( VA) ), TRICARE, Puerto Rico State Insurance, or any government patient or drug assistance program. Offer not valid for cash paying patients. The patient must be a resident of the United States, Puerto Rico or United States territories. This copy of the program is void where prohibited by state law and on the date a generic AB equivalent exists for ORGOVYX. Some rules and restrictions apply. This offer is not insurance. This offer cannot be combined with any other coupon, free trial, discount, prescription savings card or other offer. This offer is not conditional on any previous, current or future purchases, including refills. The patient and Participating Pharmacist agree that no portion of the benefits the patient receives through this copayment program will be reimbursed for all. The patient and participating pharmacist agree to report receipt of Copay Program benefits to any insurer or other third party that pays or pays for any portion of a prescription filled with the card, as such insurer, or as required by ' a third party. Myovant Sciences reserves the right to cancel, cancel or modify this offer without notice. The ORGOVYX copy program is valid until December 31, 2024.
Did you know that some Medicare Part D patients get extra help for brand prescriptions and are eligible for reduced copays?
Make All Copays Count
Through the Myovant Patient Assistance Program, eligible patients can receive ORGOVYX free of charge. 1-833-ORGOVYX (1-833-674-6899).
* This coverage information is provided for informational purposes only; Individual plans vary, and this may not include all plans. Myovant and Pfizer make no representation or warranty regarding coverage or payment for Orgovyx; Please check with individual payers for plan-specific coverage and payment information and requirements. Nothing herein shall be construed as an endorsement, approval, recommendation, representation or warranty of any plan or insurer cited. This information is subject to change without notice. Data in the file. Form data provided by MMIT, LLC as of February 2023. Transfer data provided by the SHS database as of January 2023.
Prolongation of the QT/QTc interval: Androgen deprivation therapy, such as ORGOVYX, may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, heart failure, or frequent electrolyte disturbances and in patients with long QT intervals. Take medications that are known to prolong. Electrolyte disturbances must be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.
Hypersensitivity: Angioedema was reported in 0.2% of patients treated with ORGOVYX in heroin. Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported in the post-marketing setting with ORGOVYX. Advise patients who experience any signs of hypersensitivity to temporarily discontinue ORGOVYX and seek immediate medical attention. For severe hypersensitivity reactions, discontinue ORGOVYX and administer as clinically indicated.
Incytecares For Opzelura Patient Assistance Program
Feto-fetal toxicity: The safety and efficacy of ORGOVYX in women has not been established. Based on findings and mechanism of action in animals, ORGOVYX may cause fetal harm and pregnancy loss when administered to a pregnant woman. Advise men with female partners of fertile potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX.
Laboratory investigation: Treatment with ORGOVYX causes suppression of the pituitary gonadal system. The results of diagnostic tests of pituitary gonadotropic and gonadal function performed during and after ORGOVYX may be affected. The effects of ORGOVYX therapy should be monitored periodically by measuring prostate-specific antigen (PSA) serum concentrations. If PSA is elevated, serum testosterone concentrations should be measured.
Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions occurring in ≥0.5% of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), bleeding (0.6%) and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX, including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and nonfatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX.
The most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) in patients receiving ORGOVYX were hot flushes (54%), increased glucose (44%), increased triglycerides (35%), Myalgia (30% ), decreased hemoglobin (28%), increased alanine aminotransferase (27%), fatigue (26%), aspartate aminotransferase (18%), constipation (12%) and diarrhea (12%).
Co Payment Assistance Foundation
Co-administration of ORGOVYX with a P-gp inhibitor increases the area under the curve (AUC) and maximum concentration (C).
Of ORGOVYX, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If simultaneous administration is impossible, take ORGOVYX first, separate doses by at least 6 hours, and monitor patients frequently for adverse reactions. ORGOVYX treatment may be interrupted for up to 2 weeks for a short course of treatment with P-gp inhibitors. If treatment with ORGOVYX is interrupted for more than 7 days, resume administration of ORGOVYX with a loading dose of 360 mg on day 1, then 120 mg once daily.
Of ORGOVYX, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with concomitant P-gp and strong CYP3A inducers. If simultaneous administration is not possible, increase the dose of ORGOVYX to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume ORGOVYX at the recommended dose of 120 mg once daily.
ORGOVYX® (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
Patient Assistance Reimbursement Guide 2019
Please provide the following information about yourself so that we can put you in touch with an ORGOVYX® (relugolix) representative in your area. SGLT2 and GLP1 copy-sparing program information has been compiled into a handy manual. Last updated on March 10, 2023.
Drug manufacturers sometimes offer discount cards, sometimes called copay savings coupons, that offer discounts on select drugs for your copay. If you are a patient with commercial insurance, such as through an employer, you can download a copy of the available coupon from the manufacturer's website.
Please note: If you have public insurance coverage, such as Medicare, Medicaid, or VA/Tricare, you will not be eligible for most commercial copay savings card programs.
Patients with Medicare Part D and below a certain income level may be eligible for free prescriptions through the drug manufacturer's Patient Assistance Program (PAP). See our PAP referral guide for individuals with Medicare Part D
Z Save® Patient Support Program
Support for the Michigan Collaborative on Type 2 Diabetes is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnership Program. BCBSM's Value Partnership Program provides clinical and operational support for all CQI programs. For more information about Value Partnerships, visit www.valuepartnerships.com. Although operated in partnership with Blue Cross Blue Shield of Michigan and the Michigan Collaborative on Type 2 Diabetes, the views, beliefs and opinions expressed by do not necessarily reflect the views, beliefs or opinions of BCBSM or any of its employees. Copay assistance programs, and their successors, remain in the spotlight — physician groups say the programs are "collective" and "incremental."
Prolia assistance for medicare patients, repatha assistance for medicare patients, medicare copay assistance, prolia copay assistance for medicare patients, enbrel copay assistance for medicare patients, prescription assistance for medicare patients, forteo copay assistance for medicare patients, medicare copay assistance programs, xarelto assistance for medicare patients, copay assistance programs for medicare patients, copay assistance for cancer patients, enbrel assistance for medicare patients
